Indeed. The media articles have used the word "low" although the...

Indeed. The media articles have used the word "low" although the word "low" cannot be found anywhwere in the report.

The media articles say the positive outcome was "15%" but the 15% was only for the complete cytogenetic response.

The major cytogenetic response was 25% (in addition to the 15%).

Whilst I do not understand fully, the report states the following, which sounds very positive:

"Major cytogenetic response is an accepted surrogate for prolonged survival and was used as the basis of the approvals for imatinib, dasatinib, and nilotinib.

For CML-AP and CML-BP, hematologic responses are considered the primary endpoints that are predictive of clinical benefit. CML has three phases representing a disease continuum: chronic (CML-CP), accelerated (CML-AP), and blast phase (CML-BP).

The primary endpoints were the proportion of patients achieving the following responses:

CML-CP patients: Major cytogenetic response (MCyR) or complete hematologic response (CHR) CML-AP or CML-BP patients:

CHR, no evidence of leukemia (NEL), or return to chronic phase (RCP)"